Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE versus DRIXORAL PLUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE versus DRIXORAL PLUS.
AZELASTINE HYDROCHLORIDE vs DRIXORAL PLUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine hydrochloride is a phthalazinone derivative that exerts its effect by competitively inhibiting histamine at the H1 receptor site. It also stabilizes mast cells, reducing the release of inflammatory mediators such as histamine, leukotrienes, and cytokines. This dual action provides both antihistaminic and anti-inflammatory effects.
DRIXORAL PLUS contains dexbrompheniramine, an antihistamine that competes with histamine for H1-receptor sites, suppressing histamine-induced symptoms; and pseudoephedrine, a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
1 spray (137 mcg) per nostril twice daily; ophthalmic: 1 drop in affected eye(s) twice daily.
1 tablet orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 22 hours (range 20–25 hours) following oral administration, supporting twice-daily dosing. For ophthalmic and intranasal routes, systemic half-life is similar due to absorption.
Pseudoephedrine: ~9-16 hours (pH-dependent, longer in alkaline urine). Dexbrompheniramine: ~20-25 hours. Clinical context: multiple dosing accumulates.
Approximately 75% of the dose is excreted in feces as unchanged drug and metabolites; about 25% is excreted renally, with less than 10% as unchanged drug.
Renal: 50-70% unchanged for pseudoephedrine; hepatic metabolism for dexbrompheniramine with renal excretion of metabolites.
Category C
Category C
Antihistamine
Antihistamine/Decongestant